Prof Bullinger speaks with ecancer at EHA 23 about the clinical implications for mutations detected in AML patients cells. He highlights key mutations including p53, IDH and Flt3 mutations, some of which are treatable with targeted agents such as...
Original Article: The mutational landscape of AML